alpha-Glucosidase inhibition in obesity

Area of Science:

• Pharmacology
• Metabolic Diseases
• Obesity Research

Background:

• Acarbose is an alpha-glucosidase inhibitor that impacts carbohydrate digestion in the small intestine.
• Obesity is a complex metabolic disorder with significant health implications.
• Understanding the therapeutic potential of acarbose in obesity management is crucial.

Purpose of the Study:

• To evaluate the preventive and therapeutic properties of acarbose in obesity treatment.
• To investigate the effects of acarbose on plasma insulin and blood glucose levels.
• To assess the long-term relapse prevention efficacy of acarbose in weight-reduced obese individuals.

Main Methods:

• Dose-response studies with sucrose loads in humans to measure insulin and glucose.
• Long-term tolerance testing and a double-blind, cross-over study in obese women.
• Animal studies in Sprague-Dawley rats (growing and adult) under pair-feeding and ad libitum conditions.

Main Results:

• Acarbose reduced insulin in a dose-dependent manner during sucrose loads; glucose reduction was moderate and not dose-dependent.
• The drug significantly reduced the relapse rate in weight-reduced obese women with frequent but mild side effects (flatulence, meteorism).
• In growing rats, acarbose retarded body weight and lipid depot development, even with increased food intake; effects were less pronounced in adult rats.

Conclusions:

• Acarbose induces carbohydrate malabsorption, reducing insulin levels through decreased glycemic stimulus and other mechanisms.
• Acarbose is the first tested drug showing long-term relapse reduction after weight loss.
• Animal data suggest acarbose's potential value in obesity prevention by retarding lipid accumulation.